In a recent feature for China Pharmaceutical Economics News, CEO James Wang shared the group's concrete operating practices under its "long-termism" philosophy. He emphasized that international pharmaceutical cooperation cannot be driven by short-term visibility — it requires sustained investment in compliance systems, talent development and partner trust.
Wang explained that the group develops a three-year commercialization roadmap for every partnership product, treating regulatory approval not as a project endpoint but as the starting point for market operations. This approach demands cross-functional collaboration skills and whole-lifecycle product understanding from the team.
Asked how the group balances long-term investment with near-term returns, he responded: "One of our criteria for selecting partners is whether they also believe in the long view. When both sides share that conviction, short-term milestones and pacing become much clearer."
Future updates will continue to focus on compliance, quality and cross-border coordination as key milestones progress.